Home/Filings/4/0001737287-25-000009
4//SEC Filing

Douglas Earl Martin 4

Accession 0001737287-25-000009

CIK 0001737287other

Filed

Jan 27, 7:00 PM ET

Accepted

Jan 28, 8:16 PM ET

Size

6.7 KB

Accession

0001737287-25-000009

Insider Transaction Report

Form 4
Period: 2025-01-24
Douglas Earl Martin
SVP, General Counsel
Transactions
  • Award

    Stock Option (Right to buy)

    2025-01-24+512,370512,370 total
    Exercise: $1.94Exp: 2035-01-24Common Stock (512,370 underlying)
  • Award

    Common Stock

    2025-01-24+144,928594,252 total
Footnotes (1)
  • [F1]25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Issuer

Allogene Therapeutics, Inc.

CIK 0001737287

Entity typeother

Related Parties

1
  • filerCIK 0001362155

Filing Metadata

Form type
4
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 8:16 PM ET
Size
6.7 KB